Zazove Associates’s NovoCure NVCR Stock Holding History

Zazove Associates’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,744	Closed	-$495K	–	155
2021 Q1	$495K	Buy	+3,744	New	+$592K	0.06%	101

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zazove Associates's NVCR Position: Q2 2021 in Review

Zazove Associates sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 3,744 shares — an estimated $495K sold.

Zazove Associates first reported a position in NVCR in Q1 2021 and held it in 1 quarter. The position peaked at $495K in Q1 2021. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

Zazove Associates reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
Zazove Associates sold 3,744 NovoCure shares in Q2 2021, an estimated $495K.
Zazove Associates first reported a position in NovoCure in Q1 2021 and held it in 1 quarter.
Zazove Associates's NovoCure position peaked at $495K in Q1 2021.
361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Zazove Associates's 13F filing for Q2 2021, filed 22 Jul 2021.